Business
Valeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™
Valeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™\nPR Newswire\nMONTREAL, Dec. 9, 2020\n\n\n\nCommercial launch to impact first half 2021 revenue $30 million forecasted annual peak sales 8 years of proven in-market safety Internationally Low molecular weight heparin increasingly used to prevent COVID-19 driven complications MONTREAL, Dec. 9, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company,  announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin (\"LMWH\") biosimilars.  \n\n\n\"The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly  being adopted across the country and is expected to help provide significant savings to provincial healthcare plans\", said Steve Saviuk, President and CEO. \"With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives\".\n\"The Canadian LMWH market is in excess of $200 Million annually and our complete product line and differentiating clinical package will be a beneficial factor helping to rapidly secure market share in provinces across Canada,\" added Mr. Saviuk.\nIn addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization's (\"WHO\") issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.\nDig...